BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma - News-Medical.Net

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends ® Yervoy and Zelboraf report, in which 103 U.S.-based ...

For the Treatment of Advanced Melanoma, Oncologists Report that Yervoy and Zelboraf have Joined Temodar as the Leading Agents for First-line Therapy - PharmiWeb

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical ...

Immunotherapy Drugs: Two Drugs Harness Immune System To Fight Cancer - Huffington Post

Two drugs based on immunotherapy are already available and have met with mixed results. Bristol-Myers Squibb's Yervoy has been hailed as a major breakthrough for treatment of melanoma since its approval last year, while Dendreon Corp's Provenge ...

Bristol-Myers Squibb's Thud Heard Round the World - msnbc.com

The key to Bristol-Myers' success hinges on three key developments. First, the success of melanoma cancer treatment Yervoy is imperative to kick-starting Bristol's growth. At a price of $120,000, the four-course treatment spread over three ...

Drug makers shifting towards targeted cancer drugs - Marketwatch

Last year, in addition to the introduction of Zelboraf, the FDA also approved Bristol-Myers Squibb's Yervoy treatment for melanoma. Both drugs were shown to improve survival in clinical studies. Separately, Roche plans to present updated overall ...

Plavix Set to Lose Patent Protection - New York Times

Last year, the company won approval of a drug to treat melanoma, Yervoy. In June, the Federal Drug Administration is expected to decide on approval of a blood-thinning drug, Eliquis, that Bristol-Myers is developing in partnership with Pfizer.

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

The data further characterize the Company’s cancer immunotherapies, including YERVOY ® (ipilimumab) in metastatic melanoma, anti-PD-1 (BMS-936558) and elotuzumab, and support the potential role of immuno-oncology in the treatment of a range of cancers.

Vical's CEO Presents at Bank of America Merrill Lynch Health Care Conference Call (Transcript) - Seekingalpha.com

The most important thing is the newly approved drug therapy, immunotherapy Yervoy which is known as CTLA mAb. In animal studies we’ve shown that we’ve synergy with our therapy, a combination of Allovectin and CTLA mAb actually did better than CTLA mAb ...

NeuVax Developer Dr. Peoples Eliminates Speculation For Facts - Seekingalpha.com

Companies and/or drugs discussed in this interview: Dendreon's Provenge, Bristol-Myers' (BMY) Yervoy, Eli Lilly's Raloxifene, GlaxoSmithKiline's Tykerb, and Galena BioPharma's NeuVax.